Dendritic cell product (Activartis)

N/A

Report date: 2022/11/25 18:10:35

Base Information

Drug NameDendritic cell product (Activartis)

Drug Alias NameTrivax cancer vaccine树突状细胞产品 - ActivartisAV-0113

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulantsCytotoxic T lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustria

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesTrimed Biotech

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesActivartis Biotech Gmbh

Active IndicationsN/A

Inactive IndicationsSolid tumoursGlioblastoma

Other Information

ATC CodeN/A